Nature Communications
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
Nature Communications
May 18, 2024, 14:15 |
Insight
Tracey O’Brien: Melanoma Institute Australia is moving the dial in understanding and personalizing treatment melanoma for AYA
Tracey O’Brien shared a post by Melanoma Institute Australia on LinkedIn, adding: "The most common…
May 14, 2024, 08:56 |
Insight
UCLA: Adding immune-boosting agent to personalized cancer vaccine supercharges the body's immune defense against malignant brain tumors
The combination of poly-ICLC with an immunotherapy vaccine utilizing dendritic cells is a promising approach…
May 13, 2024, 13:41 |
Insight
Innovative stem cell model provides insight into childhood cancer origins
Researchers from the University of Sheffield and St. Anna Children’s Cancer Research Institute have created…
May 6, 2024, 07:29 |
Insight
Center for Cancer Immune Therapy - Molecular patterns of resistance to immune checkpoint blockade in melanoma
Center for Cancer Immune Therapy shared on LinkedIn: "Molecular patterns of resistance to immune checkpoint…
May 1, 2024, 10:36 |
Opinion
Kai-Cheng Hsu: How polygenic scores can enhance disease prediction
Kai-Cheng Hsu shared a post on LinkedIn: "I am thrilled to announce that our groundbreaking research…
May 1, 2024, 01:32 |
Blog
Kai-Cheng Hsu: Our groundbreaking research on the ‘Utility of polygenic scores across diverse diseases in a hospital cohort for predictive modeling
Kai-Cheng Hsu, Chief Medical Officer of Biomedical Technology and Device Research Laboratories in Industrial Technology…
May 1, 2024, 01:17 |
Blog
Jun Qi: Our article on EP300/CBP bromodomain inhibition in Group 3 medulloblastoma is now published
Jun Qi, Assistant Professor of Medicine at Dana-Farber Cancer Institute, shared a post on LinkedIn:…
Apr 29, 2024, 00:46 |
Blog
Sonia Guedan: How CAR affinity influences CAR-T cell sensitivity to PD1/PD-L1 inhibition
Sonia Guedan, Cancer Immunologist at Hospital Clinic Barcelona, posted on X/Twitter: "Excited to share that…
Apr 2, 2024, 05:37 |
Drugs
Paolo Tarantino: The OXEL trial is out on Nature Communications
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on…
Mar 15, 2024, 18:24 |
Drugs
Paolo Tarantino: Final analysis of the PEONY phase 3 trial
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on…
1
2
All:
17
Posts:
1 - 10
OncoInfluencers: Dialogue with Rob Pieters, hosted by Shushan Hovsepyan
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Facebook
RSS Feed
Twitter
Linkedin
Youtube